📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3W97574

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4B6SpW4

📑 This JAMA Oncology review discusses #Chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #BreastCancer. ja.ma/3UlZi5o

📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health. ➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day. 🔗 Learn more: ja.ma/48a7OYp

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/4B5fVmv

Presented at #ESMO26 from @JAMA_current: In low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor-negative disease. ja.ma/3W0Jp4W

Presented at #ESMO26 from @JAMA_current: For low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs chemotherapy in both chemotherapy-naive patients and the overall population. ja.ma/4dRU6Nf

In Denmark, #Meningioma incidence increased from 2010 to 2023, but #Surgery and #Radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. ja.ma/47UVE5A

Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/4zvbb83

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/47Py4XY

#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/47lx9hP

In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4zwEtTG

Among men with #ProstateCancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #MetabolicSyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. ja.ma/4ilWGgU

Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference. ja.ma/4hRo6Ly

For patients with #RenalCellCarcinoma and #InferiorVenaCava tumor thrombus, neoadjuvant #StereotacticAblativeRadiotherapy before surgery appeared feasible, with no 90-day mortality or grade 4-5 radiation toxicities. ja.ma/4ys68o7

For localized deficient mismatch repair or microsatellite instability–high #GastricCancer and gastroesophageal junction adenocarcinoma, neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival. ja.ma/4ilCUSJ

The JAMA Network announces @JAMA_AI_, a new peer-reviewed online journal dedicated to the science of artificial intelligence, digital health, and emerging technologies that are transforming medicine and health care. Led by inaugural Editor in Chief Roy H. Perlis, MD, MSc, JAMA AI will publish research spanning the full spectrum of AI in health care, from advances in AI capabilities and clinical applications to rigorous evaluation and real-world implementation. The journal will begin accepting submissions in early 2027. ➡️ Learn more and sign up for updates: ja.ma/4z26fYg

💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring. ja.ma/4B1XcrR

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/4jeZsFT

💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring. ja.ma/4AYXyQ6